NovoCure Ltd. (NASDAQ:NVCR) shares saw an uptick in trading volume on Friday . 883,600 shares were traded during mid-day trading, an increase of 99% from the previous session’s volume of 445,093 shares.The stock last traded at $7.37 and had previously closed at $8.09.

Several research firms recently commented on NVCR. Deutsche Bank AG dropped their price target on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday. Barclays PLC dropped their price target on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Friday. JPMorgan Chase & Co. dropped their price target on shares of NovoCure from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday. Zacks Investment Research lowered shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. Finally, Wedbush restated an “outperform” rating and set a $30.00 price target on shares of NovoCure in a research report on Tuesday, May 10th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $21.43.

The company’s market cap is $641.26 million. The stock’s 50 day moving average is $11.24 and its 200 day moving average is $12.76.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.11. The firm had revenue of $17.90 million for the quarter, compared to analyst estimates of $15.90 million. Equities research analysts forecast that NovoCure Ltd. will post ($1.49) EPS for the current year.

In other news, COO Michael J. Ambrogi sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares in the company, valued at approximately $3,966,788.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several hedge funds recently modified their holdings of the company. Hartline Investment Corp bought a new stake in shares of NovoCure during the fourth quarter valued at $1,143,000. Century Capital Management LLC acquired a new stake in NovoCure during the fourth quarter valued at approximately $2,970,000. Finally, Morgan Stanley acquired a new stake in NovoCure during the fourth quarter valued at approximately $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.